Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Bowden

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancers|June 10, 2022
PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow UpSean Ong, Claire Pascoe, Brian D Kelly, et al.
AIDS Education and Prevention : Official Publication of the International Society for AIDS Education|October 28, 2006
Using community-based participatory research to develop an intervention to reduce HIV and STD infections among Latino menScott D Rhodes, Kenneth C Hergenrather, Jaime Montaño, et al.
Radiation Oncology (London, England)|July 25, 2022
Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trialAndrew W See, Patrick Bowden, Geoffrey Wells, et al.
BJU International|May 16, 2023
Can <sup>68</sup> Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?Yash Khanna, Vidyasagar Chinni, Kavitha Gnanasambantham, et al.
International Journal of Radiation Oncology, Biology, Physics|February 12, 2011
Benchmarking dosimetric quality assessment of prostate intensity-modulated radiotherapySashendra Senthi, Suki S Gill, Annette Haworth, et al.
Clinical and Translational Radiation Oncology|March 31, 2025
Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter studyMaximilien Rogé, Patrick Bowden, Paul Conway, et al.
BJU International|January 8, 2026
Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?Yash Khanna, Vidyasagar Chinni, Kavitha Gnanasambantham, et al.
International Journal of Cancer|June 20, 2024
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trialAndrew W See, Paul Conway, Mark Frydenberg, et al.
BJU International|June 25, 2020
Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancerAngelyn Anton, Olfat Kamel Hasan, Zita Ballok, et al.
International Journal of Cancer|June 15, 2019
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trialPatrick Bowden, Andrew W See, Mark Frydenberg, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancers|June 10, 2022
PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow UpSean Ong, Claire Pascoe, Brian D Kelly, et al.
AIDS Education and Prevention : Official Publication of the International Society for AIDS Education|October 28, 2006
Using community-based participatory research to develop an intervention to reduce HIV and STD infections among Latino menScott D Rhodes, Kenneth C Hergenrather, Jaime Montaño, et al.
Radiation Oncology (London, England)|July 25, 2022
Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trialAndrew W See, Patrick Bowden, Geoffrey Wells, et al.
BJU International|May 16, 2023
Can <sup>68</sup> Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?Yash Khanna, Vidyasagar Chinni, Kavitha Gnanasambantham, et al.
International Journal of Radiation Oncology, Biology, Physics|February 12, 2011
Benchmarking dosimetric quality assessment of prostate intensity-modulated radiotherapySashendra Senthi, Suki S Gill, Annette Haworth, et al.
Clinical and Translational Radiation Oncology|March 31, 2025
Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter studyMaximilien Rogé, Patrick Bowden, Paul Conway, et al.
BJU International|January 8, 2026
Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?Yash Khanna, Vidyasagar Chinni, Kavitha Gnanasambantham, et al.
International Journal of Cancer|June 20, 2024
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trialAndrew W See, Paul Conway, Mark Frydenberg, et al.
BJU International|June 25, 2020
Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancerAngelyn Anton, Olfat Kamel Hasan, Zita Ballok, et al.
International Journal of Cancer|June 15, 2019
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trialPatrick Bowden, Andrew W See, Mark Frydenberg, et al.
Pageof 3